- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.08. | FDA approves PTC Therapeutics' Sephience to treat rare metabolic disorder PKU | ||
| 14.08. | Motivating low-performance teams | ||
| 13.08. | GSK and Hengrui enter multi-programme collaboration agreement worth $12bn | ||
| 13.08. | AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata | ||
| 13.08. | Celebrating the Cannes Lions International Festival of Creativity | ||
| 12.08. | Novo Nordisk's Alhemo approved by FDA for expanded haemophilia use | ||
| 12.08. | Biogen/Eisai's Alzheimer's drug Leqembi shows continued benefit over four years | ||
| 12.08. | Embracing uncertainty in precision medicine communications for lung cancer | ||
| 11.08. | FDA unveils PreCheck programme to enhance US domestic pharma supply chain | ||
| 11.08. | Eli Lilly's Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients | ||
| 11.08. | Patient activation: time to think differently about treatments… | ||
| 08.08. | MSD receives NICE recommendation for Keytruda in advanced endometrial cancer | ||
| 08.08. | Novo Nordisk appoints Maziar Mike Doustdar as president and CEO | ||
| 08.08. | Maximising impact in medical communications: where are we now and where are we heading? | ||
| 07.08. | Roche's Evrysdi tablets approved by MHRA to treat spinal muscular atrophy | ||
| 07.08. | Apogee Therapeutics' atopic dermatitis candidate shows promise in phase 2 study | ||
| 07.08. | Empower or fall behind: why true patient engagement is pharma's competitive edge | ||
| 06.08. | AstraZeneca's Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer | ||
| 06.08. | Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study | ||
| 06.08. | Patient activation - not just a strategy but a necessity | ||
| 05.08. | BMS and Bain Capital launch new company to develop immunology therapies | ||
| 05.08. | CHMP recommends BeOne Medicines' Tevimbra for new lung cancer indication | ||
| 05.08. | Solving the patient engagement value equation | ||
| 04.08. | Biogen's Qalsody granted MHRA approval to treat rare form of motor neurone disease | ||
| 04.08. | FDA grants fast track designation to Nektar's rezpegaldesleukin in alopecia areata |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .